Screener
Capricor Therapeutics CAPR Business Segments — Labor And Related Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Total revenue | Three months ended March 31, 2026 / — | Three months ended March 31, 2025 / — |
|---|---|---|
| Depreciation and amortization | 281,315 | 214,964 |
| Total research and development expense | 27,376,912 | 18,915,572 |
| General and administrative expense: | ||
| Compensation and benefits | 2,234,948 | 1,500,843 |
| Other G&A segment expenses (2) | 4,115,764 | 1,375,233 |
| Total general and administrative expense, excluding non-cash expense | 6,350,712 | 2,876,076 |
| Stock-based compensation expense | 2,791,874 | 3,000,814 |
| Depreciation and amortization | 253,355 | 190,486 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's business segments — labor and related expense?
- Capricor Therapeutics (CAPR) reported business segments — labor and related expense of $2.23M in Q1 2026.
- What does business segments — labor and related expense mean?
- This metric measures the direct cash compensation, benefits, and payroll-related costs for personnel assigned to the primary business segment. It serves as a proxy for the human capital investment required to maintain operational and administrative functions. Analyzing this helps assess the company's fixed cost structure and its ability to manage workforce-related overhead.
Ask your AI about Capricor Therapeutics's business segments — labor and related expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude